linjc16/ctgov huggingface dataset:
Cluster Headache and SPINK-1 Gene

Study Overview
=================
Brief Summary
-----------------
Cluster headache (CH) is a rare, excruciating primary headache disorder. A genetic basis has been suggested by family and twin studies, but the mode of transmission seems to vary and the amount of heritability is unclear. The number of genetic association studies investigating variants implicated in the pathophysiology of CH is limited. The HCRTR2 1246G > A and the ADH4 925A > G polymorphisms have been associated with CH. The former has been confirmed and may affect the hypothalamic hypocretin system. The aim of the present study was to investigate the possible link between SPINK 1 gene and cluster headache.

Official Title
-----------------
Cluster Headache and SPINK-1 Gene

Conditions
-----------------
Episodic or Chronic Cluster Headache

Intervention / Treatment
-----------------
* Genetic: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People aged 18 or over Patient consulting in Marseille's or Nice's Pain departments Patient agreeing to participate to the research study Patient with health insurance Exclusion Criteria: People aged under 18 Patient refusing to participate to the research study Patient with deprivation of liberty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patient<br>patient with Cluster headache | Genetic: blood sample<br> <br> |
| Other: healthy subject<br>patient without Cluster headache | Genetic: blood sample<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SPINK1 genotyping |  | 2 months |
Comprehensive DNA Methylation Profiling in Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
Previous studies have indicated that abnormal DNA methylation frequently occurs in the mucosa in Crohn's disease. Comprehensive DNA methylation profiling of the inflamed and non-inflamed ileal mucosa of patients with Crohn's disease was performed. Genome-wide DNA methylation was determined using the Illumina HumanMethylation 850k BeadChip.

Official Title
-----------------
Comprehensive DNA Methylation Profiling of Inflammatory and Non-Inflammatory Mucosa in Crohn's Disease

Conditions
-----------------
Crohn Disease, Methylation, Illumina Human Methylation 850k BeadChip

Intervention / Treatment
-----------------
* Genetic: Genome-wide DNA methylation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active Crohn's disease(CDAI score≥ 150) Exclusion Criteria: No ileal lesions Under treatment of immunomodulators, biologic agents or steroids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Inflamed CD group<br>Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients | Genetic: Genome-wide DNA methylation<br>* Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.<br>|
| Non-inflamed CD group<br>Non-inflamed ileal mucosa was obtained from normal sites of active CD patients | Genetic: Genome-wide DNA methylation<br>* Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.<br>|
| Control group<br>Control ileal mucosa was obtained from healthy patients | Genetic: Genome-wide DNA methylation<br>* Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intestinal inflammation under colonoscopy | Intestinal ulcer or enteritisis observed under colonoscopy | Jan 2017 to Sep 2017 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CDAI | Crohns Disease Activity Index is measured. | Jan 2017 to Sep 2017 |
Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease

Study Overview
=================
Brief Summary
-----------------
Purpose : to evaluate the efficacy of ECP in children with refractory acute GVHD This study addresses patients with persistent GVHD after steroid and/or monoclonal antibody therapy

Detailed Description
-----------------
One arm. Six sessions in two weeks. Classification in complete response (resolution of all signs of GVHD), partial response (improvement of at least one grade) or absence of response (Glucksberg criteria). Tapering depending on patient condition during weeks 2 to 10. Final evaluation at week 10. Steroid therapy tapering at the discretion of the investigator.

Official Title
-----------------
Evaluation of Extracorporeal Photochemotherapy in Children and Young Adults With Refractory Acute Graft Versus Host Disease After Allogeneic Stem Cell Transplantation

Conditions
-----------------
Graft Versus Host Disease

Intervention / Treatment
-----------------
* Procedure: ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 0 to 30 years Acute GVHD refractory to steroids (disease progression after 2 days or absence of response after 4 days) and/or second line therapy (absence of response after 8 days) patient consent and/or parent consent Exclusion Criteria: less of 10 kgs BW clinical or biological state precluding the apheresis previous GVHD therapy with anti-lymphocyte serum (excepted in the conditioning regimen)

Ages Eligible for Study
-----------------
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GVHD grading |  | during weeks 2 to 10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival Incidence of chronic GVHD |  | during weeks 2 to 10 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
0 to 30 years, Refractory Acute GVHD
Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the impact of the serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) on etiology and prognosis of acute respiratory distress syndrome (ARDS)

Detailed Description
-----------------
The triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, is upregulated on phagocytic cells in the presence of bacteria or fungi infection and weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form (sTREM-1) in body fluids. The level and serial change of a serum sTREM-1 from cirtical ill patients has been shown to be a good diagnostic and prognostic indicator of ventilation associated pneumonia (VAP) and severe sepsis.

Official Title
-----------------
Serial Changes of sTREM-1 Levels in Patients With Acute Respiratory Distress Syndrome

Conditions
-----------------
Acute Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fulfill clinical diagnosis of ARDS Require mechanical ventilation support Exclusion Criteria: Pregnant Immunocompromised

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | 28 days | 
| Septic or non-septic etiology |  | At enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CRP, lactate, WBC count, APACHE II score, LIS, SOFA score |  | At enrollment | 
| IL-1 beta, IL-8, TNF-alpha |  | serial follow up at Day 1, 3, 5, 7, 14 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute respiratory distress syndrome, soluble triggering receptor expressed on myeloid cells-1, prognosis
Congenital Naevi of Lower Limb in the Child

Study Overview
=================
Brief Summary
-----------------
Depending on its dimensions, it is difficult to predict if a congenital nevi of the lower limb can be surgically removed by a unique simple procedure or by a complex procedure (expander, skin graft etc..), with a good result. This study retrospectively reviewed the practice of our team of surgeons depending on the size of the naevus to reveal a dimension threshold that can be used in the future to help to choose between a simple or a complex procedure.

Detailed Description
-----------------
Retrospective study using medical file data only. No intervention nor phone call etc.. to the patients or their parents.

Official Title
-----------------
Congenital Nevi in the Lower Limb in Children : Which Size Can be Afforded by a Simple Surgical Procedure ?

Conditions
-----------------
Congenital Melanocytar Nevi in the Lower Limb

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Child + congenital nevi in the lower limb + had removal surgery Exclusion criteria: - More than one congenital nevi in the lower limb.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nevi Estimated Size | Nevi Estimated Size (centimeters) | within three weeks after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post-operative complications depending on the initial size of the naevus | post-operative complications depending on the initial size of the naevus : percentage of complication rate | assessed within 6 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
naevus, congenital nevi, Congenital skin neoplasm, Reconstructive surgical procedures
Lactate and Complications in Cytoreduction Surgery for Peritoneal Carcinomatosis

Study Overview
=================
Brief Summary
-----------------
Serum lactate is a risk factor for postoperative complications in patients undergoing cytoreduction surgery in peritoneal carcinomatosis

Detailed Description
-----------------
Background. Cytoreduction surgery has been developed as a treatment of peritoneal carcinomatosis. However, this surgery is associated with important complications. The present study attempts to assess the relationship between lactacidemia levels and the rate of associated complications in patients undergoing cytoreduction surgery during the immediate postoperative period in a critical unit. Methods. Retrospective observational study. 57 patients underwent cytoreduction surgery during the years 2014 and 2015 at the General University Hospital of Castellón. All patients were admitted to the critical unit immediately after surgery. Lactacidemia levels at the time of admission and discharge from the critical unit were collected. Post-surgical complications that appeared during the stay in the critical unit were recorded and classified according to the Clavien-Dindo classification. Lactacidemia levels were still significantly higher in this group at the time of discharge.

Official Title
-----------------
Evaluation of the Relationship Between Lactacidemia and Postoperative Complications After Cytoreduction Surgery for Peritoneal Carcinomatosis

Conditions
-----------------
Lactacidemia and Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with peritoneal carcinomatosis who underwent cytoreduction surgery in the Multidisciplinary Unit of Abdomino-Pelvic Oncology Surgery (MUAPOS) of the University General Hospital of Castellón. Exclusion Criteria: patients without lactic acid levels in the register.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative complications | complications in patients undergoing cytoreduction surgery during the immediate postoperative period in the Intensive Care Unit (ICU) at the General Hospital of Castellón (HGCS) between 2014 and 2016. | 2014-2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lactic acid, Cytoreductive surgery, postoperative complications
Effects of Curcumin on Postprandial Blood Glucose, and Insulin in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Previous animal studies have shown that extracts of Curcumin lowers blood glucose.

Detailed Description
-----------------
To study the effect of curcumin on postprandial blood glucose and plasma concentrations of insulin in fifteen healthy subjects.

Conditions
-----------------
Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fifteen healthy subjects without symptoms or a history of gastrointestinal disease, abdominal surgery or diabetes mellitus, were included in this crossover study. Exclusion Criteria: Connective tissue disease or cerebrovascular or endocrine disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy subjects<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the ability of patients with intermediate risk of heart disease to appropriately use a Self-Management System.

Detailed Description
-----------------
The duration of treatment is 6 months.

Official Title
-----------------
A Consumer Use Study of OTC Lovastatin (CUSTOM): A 6-Month Consumer Behavior Study of the Lovastatin OTC Self-Management System

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: MK0803, lovastatin
* Behavioral: Self-Management System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be able to read and understand English without assistance. For Males: Minimum age 45 years and Maximum age N/A (No limit). For Females: Minimum age 55 years and Maximum age N/A (No limit). Exclusion Criteria: Pregnant or nursing Drug allergy

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0803, lovastatin|nan|
|Behavioral: Self-Management System|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who make appropriate decision for self-management. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who make appropriate decision to discontinue therapy or consult with a physician; the incidence of adverse experiences. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
High Blood Cholesterol Levels
Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté

Study Overview
=================
Brief Summary
-----------------
Red blood cell transfusion (RBC) is the main symptomatic treatment for severe anemia. RBC transfusion has proven its efficacy regarding mortality and morbidity, but it is not without side effects. The infectious side effects of transfusion are largely considered under control, non-infectious side effects are taking center stage. Seeking explanations for the beneficial and deleterious effects of RBC transfusions is necessary to ensure the safe and optimal use of this precious resource. The investigators aim to study the impact of donor and RBC characteristics on patient survival.

Official Title
-----------------
Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté

Conditions
-----------------
Erythrocyte Transfusion for All Conditions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 and over Erythrocyte Transfusion between 2007 and 2011 Performed at the University Hospital of Besançon or Dijon Exclusion Criteria: Transfusion of any blood product prior to January 1st, 2007

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transfused patients<br>A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erythrocyte Transfusion, Survival
Lymph Node Metastases and Arterial Ligation in Rectal Cancer Surgery

Study Overview
=================
Brief Summary
-----------------
Lymph node status is of major prognostic importance in non-metastatic rectal cancer. For oncological reasons, central arterial ligation of the inferior mesenteric artery (IMA) is suggested. However, there is no conclusive evidence presented for this procedure. This study aimed at investigating the localisation of lymph node metastases and the role of central versus peripheral arterial ligation of in rectal cancer specimens.

Detailed Description
-----------------
Prospective population-based study of specimens from patients that underwent surgical resection for rectal cancer in Västmanland County, Sweden. Specimens were divided in 3 sections (A-C) and the total amount of lymph nodes and the location of lymph node metastases were analysed. Multivariate analysis was used to explore the relationship between lymph node counts and age, gender, BMI, preoperative oncological treatment, type of surgery, tumour stage, vessel and specimen length.

Official Title
-----------------
Localisation of Mesenteric Lymph Node Metastases and Role of Level of Arterial Ligation in Rectal Cancer Surgery

Conditions
-----------------
Lymph Node Metastases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients that were curatively operated for rectal cancer in Västmanlands county 2012-2016. Exclusion Criteria: Patients that were not operated or had another type of cancer.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lymph node metastases in rectal cancer | Analyses of number and location of lymph node metastases in rectal cancer | 2012-2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rectal cancer